Dated: 24 April, 2020

Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
Mumbai-400 051

Dear Sir/Madam,

Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.
Ref: Stock Code: NSE: SHILPAMED/BSE-530549

Shilpa Medicare Limited Launches First Branded Generic Anticancer Drug - Dasatinib with all dosage Strength under brand name “DASASHIL”

The Drug Substance patent on Dasatinib was owned by Bristol-Myers-Squibb and had expired on 12 April 2020.

Shilpa Medicare Limited has launched the Indian branded generic of Dasatinib, an anti-cancer drug with a brand name “DASASHIL”.

![Image of Dasatinib products]
DASASHIL is First Branded Generic Anticancer Drug with all dosage strength 20/50/70/100 mg tablets which is used for the treatment of Chronic Myeloid Leukaemia (CML).

Current, monthly therapy cost of innovator is approximately 1.65 Lacs, with the launch of DASASHIL monthly cost of treatment will be reduced drastically to Rs. 6440/- as monthly therapy cost.

DASAHIL will revolutionise the treatment by ensuring to make therapy available for more Indian patients due to increased affordability. The products are being manufactured and supplied from the state-of-the-art US-FDA approved manufacturing facility.

Today there are around 10,000 to 15,000 new patients of CML in India, which can be benefited by DASASHIL Tablets.

This is for your information and doing the needful.

With Regards,

For SHILPA MEDICARE LIMITED

Sushil Bajaj
Chief Financial Officer